OncRef

Clinical Trial: NCT04350229

Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer

Status:

COMPLETED

Phase:

Not Applicable

Lead Sponsor:Instituto do Cancer do Estado de São Paulo
Information Provided By:Instituto do Cancer do Estado de São Paulo
Last Update Posted:2023-10-05

Study Overview

Brief Summary

Treatment for patients with high-risk breast cancer diagnoses is based on chemotherapy drugs with side effects. Dexamethasone is a drug that is part of the arsenal of pre-chemotherapy medications to prevent adverse events resulting from treatment, however common endocrine pathological conditions resulting from high doses of this corticoid are clinically evident in these individuals. The aim of this study is to evaluate the omission of corticosteroid doses as a pre-medication in cancer treatment after the second week of treatment with taxane in a curative setting.

Official Title

Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: Drug omission
  • Other: Control group

Other Study ID Numbers

  • NP 1521/19

Start Date (Actual)

2020-03-27

Primary Completion Date (Actual)

2022-06-20

Study Completion Date (Actual)

2022-06-20

Enrollment (Actual)

86

Study Type

Interventional

Phase

Not Applicable